April 14, 2020 Invitation to Business Update April 16th 2020
Posted at 09:24h
in Uncategorized
Invitation to Business Update April 16th 2020...
April 1, 2020 Vaccibody AS initiates research in infectious diseases and hires Gunnstein Norheim, former Vaccine Science Director at CEPI, to lead initiative
Posted at 07:45h
in Uncategorized
Vaccibody AS initiates research in infectious diseases and hires Gunnstein Norheim, former Vaccine Science Director at CEPI, to lead initiative...
January 27, 2020 VACCIBODY REGISTRATION AND TRADING ON NOTC
Posted at 00:40h
in quarterly-reports
Vaccibody AS will be registered on the NOTC-list as of January 27, 2020...
December 13, 2019 CALL FOR EXTRAORDINARY GENERAL MEETING
Posted at 15:41h
in quarterly-reports
Call for extraordinary general meeting 20 December 2019...
November 5, 2019 VACCIBODY ANNOUNCES INITIAL POSITIVE CLINICAL RESPONSES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER TREATED WITH VB10.NEO NEOANTIGEN CANCER VACCINE
Posted at 14:00h
in Uncategorized
VACCIBODY ANNOUNCES INITIAL POSITIVE CLINICAL RESPONSES WITH VB10.NEO NEOANTIGEN CANCER VACCINE...
November 2, 2019 VACCIBODY TO HOST CAPITAL MARKETS DAY IN OSLO ON 12TH NOVEMBER 2019
Posted at 18:05h
in Uncategorized
Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, will host its capital markets day on November 12 and is pleased to invite investors, analysts and press to presentations by the members of the company’s executive management...
October 11, 2019 VACCIBODY APPOINTS NEW CHIEF MEDICAL OFFICER
Posted at 07:34h
in Uncategorized
SIRI TORHAUG, MD APPOINTED AS NEW CHIEF MEDICAL OFFICER...
October 9, 2019 CALL FOR EXTRAORDINARY GENERAL MEETING
Posted at 09:18h
in Uncategorized
Call for extraordinary general meeting...
October 7, 2019 VACCIBODY AS TO PRESENT DATA ON VB10.NEO AT UPCOMING SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING 2019
Posted at 13:35h
in Uncategorized
VACCIBODY WILL PRESENT PRELIMINARY SAFETY, EFFICACY AND IMMUNOGENICITY RESULTS FROM ITS PHASE 1/2A (DIRECT-01) STUDY OF CANCER NEOANTIGEN VACCINE VB10.NEO IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS...